Processa Pharmaceuticals (PCSA) 10-Q10 Aug 232023 Q2 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2023	Aug. 04, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-39531
Entity Registrant Name	Processa Pharmaceuticals, Inc.
Entity Central Index Key	0001533743
Entity Tax Identification Number	45-1539785
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	7380 Coca Cola Drive
Entity Address, Address Line Two	Suite 106
Entity Address, City or Town	Hanover
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	21076
City Area Code	(443)
Local Phone Number	776-3133
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	PCSA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		24,531,474

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 8,677,133	$ 6,503,595
Prepaid expenses and other	1,220,150	1,883,134
Total Current Assets	9,897,283	8,386,729
Property and Equipment, net
Other Assets
Operating lease right-of-use assets, net	187,605	227,587
Security deposit	5,535	5,535
Total Other Assets	193,140	233,122
Total Assets	10,090,423	8,619,851
Current Liabilities
Current maturities of operating lease liability	81,890	78,896
Accounts payable	239,022	327,548
Due to licensor	189,000	189,000
Due to related parties		$ 51
Other Liability, Current, Related Party, Type [Extensible Enumeration]		Related Party [Member]
Accrued expenses	311,502	$ 403,061
Total Current Liabilities	821,414	998,556
Non-current Liabilities
Non-current operating lease liability	109,327	150,554
Total Liabilities	930,741	1,149,110
Commitments and Contingencies
Stockholders’ Equity
Common stock, par value $0.0001, 100,000,000 shares authorized: 24,631,474 issued and 24,531,474 outstanding at June 30, 2023, and 16,135,400 issued and 16,035,400 outstanding at December 31, 2022	2,463	1,614
Additional paid-in capital	80,339,418	72,016,688
Treasury stock at cost — 100,000 shares at June 30, 2023 and December 31, 2022	(300,000)	(300,000)
Accumulated deficit	(70,882,199)	(64,247,561)
Total Stockholders’ Equity	9,159,682	7,470,741
Total Liabilities and Stockholders’ Equity	$ 10,090,423	$ 8,619,851

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	24,631,474	16,135,400
Common stock, shares outstanding	24,531,474	16,035,400
Treasury stock shares	100,000	100,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating Expenses
Research and development expenses	$ 1,688,164	$ 3,137,292	$ 3,342,509	$ 5,181,912
General and administrative expenses	1,026,301	2,034,456	3,477,490	3,218,550
Operating Loss	(2,714,465)	(5,171,748)	(6,819,999)	(8,400,462)
Other Income (Expense), net	101,900	7,380	185,361	8,963
Net Operating Loss Before Income Tax Benefit	(2,612,565)	(5,164,368)	(6,634,638)	(8,391,499)
Income Tax Benefit
Net Loss	$ (2,612,565)	$ (5,164,368)	$ (6,634,638)	$ (8,391,499)
Net Loss per Common Share - Basic	$ (0.10)	$ (0.32)	$ (0.27)	$ (0.53)
Net Loss per Common Share - Diluted	$ (0.10)	$ (0.32)	$ (0.27)	$ (0.53)
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic	26,935,463	15,940,510	24,864,630	15,886,116
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Diluted	26,935,463	15,940,510	24,864,630	15,886,116

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock, Common [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2021	$ 1,571	$ 62,306,861		$ (36,823,332)	$ 25,485,100
Beginning balance, shares at Dec. 31, 2021	15,710,246
Stock-based compensation	$ 10	828,887			828,897
Stock-based compensation, shares	103,670
Acquisition of treasury stock			$ (300,000)		(300,000)
Acquisition of treasury stock, shares			(100,000)
Shares issued in connection with the Purchase Agreement with Lincoln Park	$ 12	449,988			450,000
Shares issued in connection with the Purchase Agreement with Lincoln Park, shares	123,609
Net loss				(3,227,131)	(3,227,131)
Ending balance, value at Mar. 31, 2022	$ 1,593	63,585,736	$ (300,000)	(40,050,463)	23,236,866
Ending balance, shares at Mar. 31, 2022	15,937,525		(100,000)
Beginning balance, value at Dec. 31, 2021	$ 1,571	62,306,861		(36,823,332)	25,485,100
Beginning balance, shares at Dec. 31, 2021	15,710,246
Net loss					(8,391,499)
Ending balance, value at Jun. 30, 2022	$ 1,592	65,595,106	$ (300,000)	(45,214,831)	20,081,867
Ending balance, shares at Jun. 30, 2022	15,919,317		(100,000)
Beginning balance, value at Mar. 31, 2022	$ 1,593	63,585,736	$ (300,000)	(40,050,463)	23,236,866
Beginning balance, shares at Mar. 31, 2022	15,937,525		(100,000)
Stock-based compensation	$ (1)	2,009,370			2,009,369
Stock-based compensation, shares	(18,208)
Net loss				(5,164,368)	(5,164,368)
Ending balance, value at Jun. 30, 2022	$ 1,592	65,595,106	$ (300,000)	(45,214,831)	20,081,867
Ending balance, shares at Jun. 30, 2022	15,919,317		(100,000)
Beginning balance, value at Dec. 31, 2022	$ 1,614	72,016,688	$ (300,000)	(64,247,561)	7,470,741
Beginning balance, shares at Dec. 31, 2022	16,135,400		(100,000)
Stock-based compensation	$ 6	341,498			341,504
Stock-based compensation, shares	63,882
Net loss				(4,022,073)	(4,022,073)
Shares issued in connection with capital raises, net of transaction costs	$ 843	6,351,234			6,352,077
Shares issued in connection with capital raises, net of transaction costs, shares	8,432,192
Ending balance, value at Mar. 31, 2023	$ 2,463	78,709,420	$ (300,000)	(68,269,634)	10,142,249
Ending balance, shares at Mar. 31, 2023	24,631,474		(100,000)
Beginning balance, value at Dec. 31, 2022	$ 1,614	72,016,688	$ (300,000)	(64,247,561)	7,470,741
Beginning balance, shares at Dec. 31, 2022	16,135,400		(100,000)
Net loss					(6,634,638)
Shares issued in connection with capital raises, net of transaction costs, shares	8,432,192
Ending balance, value at Jun. 30, 2023	$ 2,463	80,339,418	$ (300,000)	(70,882,199)	9,159,682
Ending balance, shares at Jun. 30, 2023	24,631,474		(100,000)
Beginning balance, value at Mar. 31, 2023	$ 2,463	78,709,420	$ (300,000)	(68,269,634)	10,142,249
Beginning balance, shares at Mar. 31, 2023	24,631,474		(100,000)
Stock-based compensation		319,123			319,123
Net loss				(2,612,565)	(2,612,565)
Warrants issued in connection with consulting agreement		1,310,875			1,310,875
Ending balance, value at Jun. 30, 2023	$ 2,463	$ 80,339,418	$ (300,000)	$ (70,882,199)	$ 9,159,682
Ending balance, shares at Jun. 30, 2023	24,631,474		(100,000)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash Flows From Operating Activities
Net loss	$ (6,634,638)	$ (8,391,499)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash lease expense for right-of-use assets	39,982	45,291
Non-cash milestone expense in connection with license agreement		189,000
Amortization of issuance costs		40,613
Amortization of intangible asset		394,248
Stock-based compensation	660,627	2,838,266
Warrants issued to purchase 3,160,130 shares of common stock in connection with a consulting agreement	1,310,875
Net changes in operating assets and liabilities:
Prepaid expenses and other	662,984	272,050
Operating lease liability	(38,233)	(47,256)
Accounts payable	(88,526)	429,199
Due (from) to related parties	(51)	(1,772)
Other receivables		70,274
Accrued expenses	(91,559)	28,147
Net cash used in operating activities	(4,178,539)	(4,133,439)
Cash Flows From Financing Activities
Net proceeds from common stock issued	6,352,077
Acquisition of treasury stock		(300,000)
Net cash provided by (used in) financing activities	6,352,077	(300,000)
Net Increase (Decrease) in Cash	2,173,538	(4,433,439)
Cash and Cash Equivalents – Beginning of Period	6,503,595	16,497,581
Cash and Cash Equivalents – End of Period	8,677,133	12,064,142
Non-Cash Financing Activities
Issuance of 123,609 shares of common stock in connection with the Purchase Agreement with Lincoln Park		$ 450,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)	6 Months Ended
	Jun. 30, 2022 shares
Purchase Agreement [Member] \| Common Stock [Member] \| Lincoln Park Capital Fund LLC [Member]
Shares issued in connection with the Purchase Agreement with Lincoln Park	123,609

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	6 Months Ended
Organization and Summary of Significant Accounting Policies	Jun. 30, 2023
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	Note 1 – Organization and Summary of Significant Accounting Policies Organization We are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our Next Generation Chemotherapy (NGC) drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution while maintaining the well-known and established existing mechanisms of killing the cancer cells. By modifying the NGC drugs in this manner, we believe our three NGC treatments will provide improved safety-efficacy profiles when compared to their currently marketed counterparts. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions of the Securities and Exchange Commission (“SEC”) on Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year. Going Concern and Management’s Plans We have incurred losses since inception, devoting substantially all of our efforts toward research and development, and have an accumulated deficit of $ 70.9 6.6 4.2 During the six months ended June 30, 2023, we raised gross proceeds of $ 7.0 6.4 8,432,192 Our condensed consolidated financial statements have been prepared using U.S. GAAP and are based on the assumption that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. We face certain risks and uncertainties that are present in many emerging pharmaceutical companies regarding product development, limited working capital, recurring losses and negative cash flow from operations, future profitability, ability to obtain future capital, protection of patents, technologies and property rights, competition, rapid technological change, navigating the domestic and major foreign markets’ regulatory and clinical environment, recruiting and retaining key personnel, dependence on third party manufacturing organizations, third party collaboration and licensing agreements, lack of sales and marketing activities. We currently have no customers or pharmaceutical products to sell or distribute. These risks and other factors raise substantial doubt about our ability to continue as a going concern. At June 30, 2023, we had cash and cash equivalents totaling $ 8.7 We had no We are hoping to raise additional funds in 2023, but will only do so if terms are acceptable to us. Additional funding may not be available to us on acceptable terms, or at all. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or planned future clinical trial plans, or research and development programs. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Uncertainty concerning our ability to continue as a going concern may hinder our ability to obtain future financing. Continued operations and our ability to continue as a going concern are dependent on our ability to obtain additional funding in the future and thereafter, and no assurances can be given that such funding will be available at all, in a sufficient amount, or on reasonable terms. Without additional funds from debt or equity financing, sales of assets, sales or out-licenses of intellectual property or technologies, or other transactions providing funds, we will rapidly exhaust our resources and be unable to continue operations. Absent additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year or more after the date that these condensed consolidated financial statements are available to be issued based on the timing and amount of our projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result, substantial doubt exists about our ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are available to be issued. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be different should we be unable to continue as a going concern based on the outcome of these uncertainties described above. Use of Estimates In preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation, intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future results of operations and cash flows. Income Taxes We account for income taxes in accordance with ASC Topic 740, Income Taxes. Under ACS 740-270 Income Taxes – Interim Reporting Concentration of Credit Risk Financial instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents. We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal Deposit Insurance Corporation (FDIC) up to specified limits. Total cash held by our banks at June 30, 2023, exceeded FDIC limits. Recent Accounting Pronouncements From time to time, the Financial Accounting Standards Board (“FASB”) or other standard setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (“ASU”). We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements. We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our consolidated financial position or results of operations.

Stockholders_ Equity

Stockholders’ Equity	6 Months Ended
Stockholders’ Equity	Jun. 30, 2023
Equity [Abstract]
Stockholders’ Equity	Note 2 – Stockholders’ Equity Preferred Stock There were no Common Stock Increase in Our Authorized Number of Shares Subsequent to receiving shareholder approval on June 27, 2023, we amended our Certificate of Incorporation to increase the number of authorized shares of our common stock from 50,000,000 100,000,000 100,000,000 During the six months ended June 30, 2023, we issued 8,432,192 shares of our common stock through several fundraising efforts described below: ATM Offering On August 20, 2021, we entered into the Sales Agreement with Oppenheimer & Co. Inc. (the “Sales Agent”) under which we may issue and sell up to $ 30.0 569,648 1.22 693,000 672,000 Lincoln Park Capital Fund, LLC Purchase Agreement On March 23, 2022, we entered into the Purchase Agreement with Lincoln Park, pursuant to which Lincoln Park has committed to purchase up to $ 15.0 1.00 50,000 1.08 54,000 Registered Direct Offering On February 14, 2023, we closed a registered direct offering (the “Offering”) for the sale of 7,812,544 0.80 6.3 5.6 The Purchase Agreement provides that, subject to certain exceptions, until the earlier of (i) 90 days after the closing of the Offering or (ii) the trading day following the date that our common stock’s closing price exceeds $2.00 for a period of 10 consecutive trading days, neither we nor our subsidiary will issue or enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or common stock equivalents. We paid the Placement Agent (“Spartan Capital” or “Spartan”) a cash fee of 8.0% 60,000 3,160,130 1.02 three years

Stock-based Compensation

Stock-based Compensation	6 Months Ended
Stock-based Compensation	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	Note 3 - Stock-based Compensation On June 19, 2019, our stockholders approved, and we adopted the Processa Pharmaceuticals Inc. 2019 Omnibus Equity Incentive Plan (the “2019 Plan”). The 2019 Plan allows us, under the direction of our Board of Directors or a committee thereof, to make grants of stock options, restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and directors. The 2019 Plan provides for the aggregate issuance of 6,000,000 931,692 shares available for future grants. Stock Compensation Expense We recorded stock-based compensation expense for the three and six months ended June 30, 2023 and 2022 as follows: Schedule of Stock-based Compensation Expense 2023 2022 2023 2022 Three Months Ended Six Months Ended 2023 2022 2023 2022 Research and development $ 102,678 $ 685,624 $ 209,526 $ 877,500 General and administrative 216,445 1,323,745 451,101 1,960,766 Total $ 319,123 $ 2,009,369 $ 660,627 $ 2,838,266 During the six months ended June 30, 2023, we also recorded an expense of $ 1.3 Stock Options During the six months ended June 30, 2023, stock options to purchase 36,885 141,611 18.22 2.6 years. Restricted Stock Awards Activity with respect to our Restricted Stock Awards (RSAs) during the six months ended June 30, 2023 was as follows: Schedule of Restricted Stock Awards (“RSAs”) Activity Number of Weighted- Outstanding at January 1, 2023 61,888 $ 4.72 Granted 90,000 1.10 Cancelled (26,118 ) 1.72 Issued (100,770 ) 1.79 Outstanding and unvested at June 30, 2023 25,000 $ 6.65 On January 1, 2023, we granted RSAs totaling 90,000 26,118 At June 30, 2023, the total unrecognized stock-based compensation expense related to the outstanding and unvested RSAs was $ 94,000 1.3 4.21 Restricted Stock Units Activity with respect to our Restricted Stock Units (“RSUs”) during the six months ended June 30, 2023 was as follows: Schedule of Restricted Stock Units (“RSUs”) Activity Number of Weighted- Outstanding at January 1, 2023 2,713,977 $ 3.69 Granted 1,473,328 0.90 Cancelled (44,395 ) 1.63 Outstanding at June 30, 2023 4,142,910 2.72 Vested and unissued 2,590,497 3.51 Unvested at June 30, 2023 1,552,413 $ 1.41 At June 30, 2023, unrecognized stock-based compensation expense of $ 1.2 1.5 322,000 3.01 Holders of our vested RSUs have our promise to issue shares of our common stock upon meeting the distribution restrictions contained in their Restricted Stock Unit Award Agreement. The distribution restrictions are different (longer) than the vesting schedule, imposing an additional restriction on the holder. Unlike RSAs, while certain employees may hold fully vested RSUs, the individual does not hold any shares or have any rights of a shareholder until the distribution restrictions are met. Upon distribution to the employee, each RSU converts into one share of our common stock. The RSUs contain dividend equivalent rights. Warrants During the six months ended June 30, 2023, we granted warrants to purchase a total of 3,160,130 shares of our common stock as compensation for services provided under an amended consulting agreement with Spartan Capital, the placement agent for the Offering . The warrants were issued and exercisable on April 17, 2023 with an exercise price of $ 1.02 and expiration date of April 17, 2026. The warrants contains both call and cashless exercise provisions. We recorded $ 1,310,875 as a general and administrative expense representing the fair value of these warrants on February 14, 2023, the date we amended the consulting agreement since there were no contingent conditions on that date through April 17, 2023, the date of issuance. 3,366,480 shares with a weighted average exercise price of $ 1.61 and a weighted average remaining contractual life of 2.5 years. At June 30, 2023, we did not have any unrecognized stock-based compensation expense related to our granted stock purchase warrants.

Net Loss per Share of Common St

Net Loss per Share of Common Stock	6 Months Ended
Net Loss per Share of Common Stock	Jun. 30, 2023
Earnings Per Share [Abstract]
Net Loss per Share of Common Stock	Note 4 – Net Loss per Share of Common Stock Net Loss Per Share Basic net loss per share is computed by dividing our net loss available to common shareholders by the weighted average number of shares of common stock outstanding (which excludes unvested RSAs and includes vested RSUs) during the period. Diluted loss per share is computed by dividing our net loss available to common shareholders by the diluted weighted average number of shares of common stock (which includes the potentially dilutive effect of stock options, unvested RSAs, unvested RSUs and warrants) during the period. Since we experienced a net loss for both periods presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the three and six months ended June 30, 2023 and 2022 excludes the impact of potentially dilutive common shares since those shares would have an anti-dilutive effect on net loss per share. The computation of net loss per share for the three- and six-month periods ended June 30, 2023 and 2022 was as follows: Schedule of Net Loss Per Share Basic and Diluted 2023 2022 2023 2022 Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Basic and diluted net loss per share: Net loss available to common stockholders $ (2,612,565 ) $ (5,164,368 ) $ (6,634,638 ) $ (8,391,499 ) Weighted average number of common shares-basic and diluted 26,935,463 15,940,510 24,864,630 15,886,116 Basic and diluted net loss per share $ (0.10 ) $ (0.32 ) $ (0.27 ) $ (0.53 ) Our diluted net loss per share for the three and six months ended June 30, 2023 and 2022 excluded 5,085,504 1,965,502

Operating Leases

Operating Leases	6 Months Ended
Operating Leases	Jun. 30, 2023
Operating Leases
Operating Leases	Note 5 – Operating Leases We lease our office space under an operating lease agreement. This lease does not have significant rent escalation, concessions, leasehold improvement incentives, or other build-out clauses. Further, the lease does not contain contingent rent provisions. Our office space lease includes both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group lease and non-lease components for all leases. We also lease office equipment under an operating lease. Our leases do not provide an implicit rate and, as such, we have used our incremental borrowing rate of 8% Lease costs included in our condensed consolidated statements of operations totaled $ 24,000 49,000 Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases Remaining lease term (years) for our facility lease 2.3 Remaining lease term (years) for our equipment lease 0.8 Weighted average remaining lease term (years) for our facility and equipment leases 2.2 Weighted average discount rate for our facility and equipment leases 8.0 % Annual lease liabilities for all operating leases were as follows at June 30, 2023: Schedule of Annual Lease Liabilities for all Operating Leases 2023 $ 47,354 2024 92,356 2025 70,040 Total lease payments 209,750 Less: Interest (18,533 ) Present value of lease liabilities 191,217 Less: current maturities (81,890 ) Non-current lease liability $ 109,327

Related Party Transactions

Related Party Transactions	6 Months Ended
Related Party Transactions	Jun. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 6 – Related Party Transactions CorLyst, LLC (“CorLyst”) reimburses us for shared costs related to payroll, health insurance and rent based on actual costs incurred, which are recognized as a reduction of our general and administrative operating expenses being reimbursed in our condensed consolidated statement of operations. We recorded $ 34,000 32,000 64,000 No

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7 – Commitments and Contingencies Purchase Obligations We enter into contracts in the normal course of business with contract research organizations (CROs) and subcontractors to further develop our products. The contracts are cancelable, with varying provisions regarding termination. If we terminated a cancelable contract with a specific vendor, we would only be obligated for products or services that we received at the effective date of the termination and any applicable cancellation fees. At June 30, 2023, we are contractually obligated to pay up to $ 2.4

Subsequent Event

Subsequent Event	6 Months Ended
Subsequent Event	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Event	Note 8 – Subsequent Event On August 8, 2023, Mr. George Ng was appointed as our Chief Executive Officer and as a Board Director. Mr. Ng is a seasoned life sciences industry executive with significant experience successfully leading small-cap public companies including through product development and fundraising activities. In connection with his employment, Mr. Ng will be paid an annual base salary of $ 400,000 100,000 800,000 400,000 400,000 200,000 10,000,000 200,000 10,000,000 Given his oncology and drug development expertise, Dr. David Young will transition to be our President, Research and Development, concentrating his fulltime effort to drug development of our NGC drugs. By mutual agreement, Mr. R. Michael Floyd resigned as Chief Operating Officer of the Company, effective August 31, 2023.

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Organization	Organization We are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our Next Generation Chemotherapy (NGC) drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution while maintaining the well-known and established existing mechanisms of killing the cancer cells. By modifying the NGC drugs in this manner, we believe our three NGC treatments will provide improved safety-efficacy profiles when compared to their currently marketed counterparts.
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions of the Securities and Exchange Commission (“SEC”) on Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year.
Going Concern and Management’s Plans	Going Concern and Management’s Plans We have incurred losses since inception, devoting substantially all of our efforts toward research and development, and have an accumulated deficit of $ 70.9 6.6 4.2 During the six months ended June 30, 2023, we raised gross proceeds of $ 7.0 6.4 8,432,192 Our condensed consolidated financial statements have been prepared using U.S. GAAP and are based on the assumption that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. We face certain risks and uncertainties that are present in many emerging pharmaceutical companies regarding product development, limited working capital, recurring losses and negative cash flow from operations, future profitability, ability to obtain future capital, protection of patents, technologies and property rights, competition, rapid technological change, navigating the domestic and major foreign markets’ regulatory and clinical environment, recruiting and retaining key personnel, dependence on third party manufacturing organizations, third party collaboration and licensing agreements, lack of sales and marketing activities. We currently have no customers or pharmaceutical products to sell or distribute. These risks and other factors raise substantial doubt about our ability to continue as a going concern. At June 30, 2023, we had cash and cash equivalents totaling $ 8.7 We had no We are hoping to raise additional funds in 2023, but will only do so if terms are acceptable to us. Additional funding may not be available to us on acceptable terms, or at all. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or planned future clinical trial plans, or research and development programs. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Uncertainty concerning our ability to continue as a going concern may hinder our ability to obtain future financing. Continued operations and our ability to continue as a going concern are dependent on our ability to obtain additional funding in the future and thereafter, and no assurances can be given that such funding will be available at all, in a sufficient amount, or on reasonable terms. Without additional funds from debt or equity financing, sales of assets, sales or out-licenses of intellectual property or technologies, or other transactions providing funds, we will rapidly exhaust our resources and be unable to continue operations. Absent additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year or more after the date that these condensed consolidated financial statements are available to be issued based on the timing and amount of our projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result, substantial doubt exists about our ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are available to be issued. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be different should we be unable to continue as a going concern based on the outcome of these uncertainties described above.
Use of Estimates	Use of Estimates In preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation, intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future results of operations and cash flows.
Income Taxes	Income Taxes We account for income taxes in accordance with ASC Topic 740, Income Taxes. Under ACS 740-270 Income Taxes – Interim Reporting
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents. We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal Deposit Insurance Corporation (FDIC) up to specified limits. Total cash held by our banks at June 30, 2023, exceeded FDIC limits.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, the Financial Accounting Standards Board (“FASB”) or other standard setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (“ASU”). We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements. We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our consolidated financial position or results of operations.

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended
Stock-based Compensation (Tables)	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-based Compensation Expense	We recorded stock-based compensation expense for the three and six months ended June 30, 2023 and 2022 as follows: Schedule of Stock-based Compensation Expense 2023 2022 2023 2022 Three Months Ended Six Months Ended 2023 2022 2023 2022 Research and development $ 102,678 $ 685,624 $ 209,526 $ 877,500 General and administrative 216,445 1,323,745 451,101 1,960,766 Total $ 319,123 $ 2,009,369 $ 660,627 $ 2,838,266
Schedule of Restricted Stock Awards (“RSAs”) Activity	Activity with respect to our Restricted Stock Awards (RSAs) during the six months ended June 30, 2023 was as follows: Schedule of Restricted Stock Awards (“RSAs”) Activity Number of Weighted- Outstanding at January 1, 2023 61,888 $ 4.72 Granted 90,000 1.10 Cancelled (26,118 ) 1.72 Issued (100,770 ) 1.79 Outstanding and unvested at June 30, 2023 25,000 $ 6.65
Schedule of Restricted Stock Units (“RSUs”) Activity	Activity with respect to our Restricted Stock Units (“RSUs”) during the six months ended June 30, 2023 was as follows: Schedule of Restricted Stock Units (“RSUs”) Activity Number of Weighted- Outstanding at January 1, 2023 2,713,977 $ 3.69 Granted 1,473,328 0.90 Cancelled (44,395 ) 1.63 Outstanding at June 30, 2023 4,142,910 2.72 Vested and unissued 2,590,497 3.51 Unvested at June 30, 2023 1,552,413 $ 1.41

Net Loss per Share of Common _2

Net Loss per Share of Common Stock (Tables)	6 Months Ended
Net Loss per Share of Common Stock (Tables)	Jun. 30, 2023
Earnings Per Share [Abstract]
Schedule of Net Loss Per Share Basic and Diluted	The computation of net loss per share for the three- and six-month periods ended June 30, 2023 and 2022 was as follows: Schedule of Net Loss Per Share Basic and Diluted 2023 2022 2023 2022 Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Basic and diluted net loss per share: Net loss available to common stockholders $ (2,612,565 ) $ (5,164,368 ) $ (6,634,638 ) $ (8,391,499 ) Weighted average number of common shares-basic and diluted 26,935,463 15,940,510 24,864,630 15,886,116 Basic and diluted net loss per share $ (0.10 ) $ (0.32 ) $ (0.27 ) $ (0.53 )

Operating Leases (Tables)

Operating Leases (Tables)	6 Months Ended
Operating Leases (Tables)	Jun. 30, 2023
Operating Leases
Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases	Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases Remaining lease term (years) for our facility lease 2.3 Remaining lease term (years) for our equipment lease 0.8 Weighted average remaining lease term (years) for our facility and equipment leases 2.2 Weighted average discount rate for our facility and equipment leases 8.0 %
Schedule of Annual Lease Liabilities for all Operating Leases	Annual lease liabilities for all operating leases were as follows at June 30, 2023: Schedule of Annual Lease Liabilities for all Operating Leases 2023 $ 47,354 2024 92,356 2025 70,040 Total lease payments 209,750 Less: Interest (18,533 ) Present value of lease liabilities 191,217 Less: current maturities (81,890 ) Non-current lease liability $ 109,327

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Accounting Policies [Abstract]
Accumulated deficit	$ 70,882,199				$ 70,882,199		$ 64,247,561
Net loss	2,612,565	$ 4,022,073	$ 5,164,368	$ 3,227,131	6,634,638	$ 8,391,499
Net cash provided by operating activities					4,178,539	4,133,439
Proceeds from sale of common stock					7,000,000
Net proceeds from sale of stock					$ 6,352,077
Sale of common stock, shares					8,432,192
Cash and cash equivalents	$ 8,677,133				$ 8,677,133		$ 6,503,595
Revenue					$ 0

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)				3 Months Ended	6 Months Ended
Stockholders’ Equity (Details Narrative) - USD ($)	Feb. 14, 2023	Mar. 23, 2022	Aug. 20, 2021	Mar. 31, 2023	Jun. 30, 2023	Jun. 30, 2022	Jun. 27, 2023	Jun. 26, 2023	Apr. 17, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Preferred stock, shares issued					0					0
Preferred stock, shares outstanding					0					0
Authorized shares of common stock					100,000,000		100,000,000	50,000,000		100,000,000
Net proceeds from common stock					$ 6,352,077
Sales Agreement [Member]
Class of Stock [Line Items]
Number of shares issued					569,648
Shares issue price per share					$ 1.22
Gross proceeds from common stock					$ 693,000
Net proceeds from common stock					$ 672,000
Sales Agreement [Member] \| Maximum [Member]
Class of Stock [Line Items]
Maximum value to be sold at the market offering			$ 30,000,000
Purchase Agreement [Member] \| Lincoln Park Capital Fund LLC [Member]
Class of Stock [Line Items]
Number of shares issued					50,000
Shares issue price per share					$ 1.08
Net proceeds from common stock					$ 54,000
Threshold price		$ 1
Purchase Agreement [Member] \| Maximum [Member] \| Lincoln Park Capital Fund LLC [Member]
Class of Stock [Line Items]
Commitment to purchase common stock		$ 15,000,000
Securities Purchase Agreement [Member] \| Registered Direct Offering [Member] \| Accredited Investor [Member]
Class of Stock [Line Items]
Number of shares issued	7,812,544
Shares issue price per share	$ 0.80
Gross proceeds from common stock	$ 6,300,000
Net proceeds from common stock	$ 5,600,000
Restrictions to issue stock	The Purchase Agreement provides that, subject to certain exceptions, until the earlier of (i) 90 days after the closing of the Offering or (ii) the trading day following the date that our common stock’s closing price exceeds $2.00 for a period of 10 consecutive trading days, neither we nor our subsidiary will issue or enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or common stock equivalents.
Securities Purchase Agreement [Member] \| Registered Direct Offering [Member] \| Placement Agent [Member]
Class of Stock [Line Items]
Cash fee percentage	8%
Reimbursement fees	$ 60,000
Consulting Agreement [Member] \| Spartan Capital Securites LLC [Member]
Class of Stock [Line Items]
Warrants to purchase common stock, shares									3,160,130
Warrant exercise price									$ 1.02
Warrant term									3 years
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued				8,432,192	8,432,192

Schedule of Stock-based Compens

Schedule of Stock-based Compensation Expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 319,123	$ 2,009,369	$ 660,627	$ 2,838,266
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	102,678	685,624	209,526	877,500
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 216,445	$ 1,323,745	$ 451,101	$ 1,960,766

Schedule of Restricted Stock Aw

Schedule of Restricted Stock Awards (“RSAs”) Activity (Details) - Restricted Stock [Member] - $ / shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of restricted stock, shares outstanding	61,888
Weighted-average grant-date fair value per share, outstanding	$ 4.72
Number of shares, granted	90,000
Weighted-average grant-date fair value per share, granted	$ 1.10	$ 4.21
Number of shares, cancelled	(26,118)
Weighted-average grant-date fair value per share, cancelled	$ 1.72
Number of shares, vested and issued	(100,770)
Weighted-average grant-date fair value per share, vested and issued	$ 1.79
Number of restricted stock shares outstanding	25,000
Weighted-average grant-date fair value per share, outstanding	$ 6.65

Schedule of Restricted Stock Un

Schedule of Restricted Stock Units (“RSUs”) Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, Beginning balance	2,713,977
Weighted-average grant-date fair value per share, Beginning balance	$ 3.69
Number of shares, granted	1,473,328
Weighted-average grant-date fair value per share, awarded	$ 0.90	$ 3.01
Number of shares, cancelled	(44,395)
Weighted-average grant-date fair value per share, cancelled	$ 1.63
Number of shares, Ending balance	4,142,910
Weighted-average grant-date fair value per share, Ending balance	$ 2.72
Number of shares, vested and unissued	2,590,497
Weighted-average grant-date fair value per share, vested and unissued	$ 3.51
Number of restricted stock shares outstanding	1,552,413
Weighted-average grant-date fair value per share, outstanding	$ 1.41

Stock-based Compensation (Detai

Stock-based Compensation (Details Narrative) - USD ($)			3 Months Ended		6 Months Ended
Stock-based Compensation (Details Narrative) - USD ($)	Feb. 14, 2023	Jan. 01, 2023	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants issued in connection with consulting agreement			$ 1,310,875
General and Administrative Expense			$ 1,026,301	$ 2,034,456	$ 3,477,490	$ 3,218,550
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants issued in connection with consulting agreement					$ 1,300,000
Weighted average exercise price	$ 1.02		$ 1.61		$ 1.61
Warrants to purchase shares			3,366,480		3,366,480
Weighted average remaining contractual life					2 years 6 months
Warrant [Member] \| Consultant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants granted					3,160,130
General and Administrative Expense	$ 1,310,875
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options, forfeited					36,885
Options exercisable, shares			141,611		141,611
Options exercisable weighted average exercise price			$ 18.22		$ 18.22
Exercisable weighted average remaining contractual term					2 years 7 months 6 days
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, granted					90,000
Number of shares, cancelled					26,118
Unrecognized share based compensation expense			$ 94,000		$ 94,000
Weighted average period for recognition					1 year 3 months 18 days
Weighted-average grant-date fair value per share					$ 1.10	$ 4.21
Restricted Stock [Member] \| Three Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, granted		90,000
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, granted					1,473,328
Number of shares, cancelled					44,395
Unrecognized share based compensation expense			$ 1,200,000		$ 1,200,000
Weighted average period for recognition					1 year 6 months
Weighted-average grant-date fair value per share					$ 0.90	$ 3.01
Unrecognized restricted stock expense					$ 322,000
2019 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Maximum equity available for issuance			6,000,000		6,000,000
Shares available for future grants			931,692		931,692

Schedule of Net Loss Per Share

Schedule of Net Loss Per Share Basic and Diluted (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share [Abstract]
Net loss available to common stockholders	$ (2,612,565)	$ (4,022,073)	$ (5,164,368)	$ (3,227,131)	$ (6,634,638)	$ (8,391,499)
Weighted average number of common shares-basic	26,935,463		15,940,510		24,864,630	15,886,116
Weighted average number of common shares-diluted	26,935,463		15,940,510		24,864,630	15,886,116
Basic net loss per share	$ (0.10)		$ (0.32)		$ (0.27)	$ (0.53)
Diluted net loss per share	$ (0.10)		$ (0.32)		$ (0.27)	$ (0.53)

Net Loss per Share of Common _3

Net Loss per Share of Common Stock (Details Narrative) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share, amount	5,085,504	1,965,502	5,085,504	1,965,502

Schedule of Weighted Average Re

Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases (Details)	Jun. 30, 2023
Property, Plant and Equipment [Line Items]
Weighted average remaining lease term (years) for our facility and equipment leases	2 years 2 months 12 days
Weighted average discount rate for our facility and equipment leases	8%
Facility Lease [Member]
Property, Plant and Equipment [Line Items]
Remaining lease term (years)	2 years 3 months 18 days
Equipment [Member]
Property, Plant and Equipment [Line Items]
Remaining lease term (years)	9 months 18 days

Schedule of Annual Lease Liabil

Schedule of Annual Lease Liabilities for all Operating Leases (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Operating Leases
2023	$ 47,354
2024	92,356
2025	70,040
Total lease payments	209,750
Less: Interest	(18,533)
Present value of lease liabilities	191,217
Less: current maturities	(81,890)	$ (78,896)
Non-current lease liability	$ 109,327	$ 150,554

Operating Leases (Details Narra

Operating Leases (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
Operating Leases (Details Narrative) - USD ($)	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating Leases
Operating lease borrowing rate	8%		8%
Lease cost	$ 24,000	$ 24,000	$ 49,000	$ 49,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - CorLyst, LLC [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Related Party Transaction [Line Items]
Rent and other costs reimbursements received	$ 34,000	$ 32,000	$ 64,000	$ 64,000
Related Party [Member]
Related Party Transaction [Line Items]
Due from related parties	$ 0	$ 0	$ 0	$ 0

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) $ in Millions	Jun. 30, 2023 USD ($)
Agreements [Member] \| Contract Research Organizations [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase obligation	$ 2.4

Subsequent Event (Details Narra

Subsequent Event (Details Narrative) - USD ($)		6 Months Ended
Subsequent Event (Details Narrative) - USD ($)	Aug. 08, 2023	Jun. 30, 2023
Restricted Stock Units (RSUs) [Member]
Subsequent Event [Line Items]
Number of shares, granted		1,473,328
Subsequent Event [Member]
Subsequent Event [Line Items]
Annual base salary	$ 400,000
Bonus compensation	$ 100,000
Subsequent Event [Member] \| Restricted Stock Units (RSUs) [Member]
Subsequent Event [Line Items]
Number of shares, granted	800,000
Subsequent Event [Member] \| Service Based RSU [Member]
Subsequent Event [Line Items]
Number of shares, granted	400,000
Subsequent Event [Member] \| First Performance Based R S U [Member]
Subsequent Event [Line Items]
Number of shares, granted	200,000
Performance vesting criteria	$ 10,000,000
Subsequent Event [Member] \| Second Performance Based R S U [Member]
Subsequent Event [Line Items]
Number of shares, granted	200,000
Performance vesting criteria	$ 10,000,000